Cassava Sciences’ stock craters after Alzheimer’s disease trial fails to meet its goals

• Sage Therapeutics to end development of key therapy after a third trial failure

  Business - MarketWatch - 6 days ago

• Cannabis stocks crater as Florida fails to garner needed votes for adult use

  Business - MarketWatch - November 6
• 

  Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results

  Business - The New York Times - Yesterday

• Bayer’s stock slumps after warning on crop-sciences unit

  Business - MarketWatch - November 12

• Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

  Business - MarketWatch - November 14

• Biogen’s stock hit by soft sales of Alzheimer’s treatment

  Business - MarketWatch - October 30

• Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial

  Business - MarketWatch - November 4

• ‘We’re living in uncertainty’: My sister has Alzheimer’s disease. How do I know the right time to take control of her finances?

  Business - MarketWatch - Yesterday

• Linde falls after its guidance fails to wow the market. We've seen this movie before

  Business - CNBC - October 31

More from MarketWatch

• Here’s how much prices of Modelo and Corona beer will have to rise to cover tariffs

  Business - MarketWatch - 15 minutes ago

• Treasury yields fall as traders await PCE inflation data

  Business - MarketWatch - 22 minutes ago

• Biden’s plan for Medicare coverage of weight-loss drugs would drive up costs by billions of dollars

  Business - MarketWatch - 6 hours ago

• Dell’s AI boost derailed slightly by Blackwell transition and slower move to AI PCs

  Business - MarketWatch - 6 hours ago

• Urban Outfitters says it doesn’t have to discount as aggressively, amid holiday-season optimism

  Business - MarketWatch - 8 hours ago